Abstract
Background:Antimicrobial resistance in Helicobacter pylori infection is an important factor leading to failure of therapy. The aim of this study was to determine the eradication rate of H pylori in type 2 diabetes mellitus and to assess the effect of clarithromycin resistance on H pylori eradication.Method:Fifty-six consecutive patients with type 2 diabetes mellitus and 58 age- and sex-matched control patients were included in the study. H pylori infection was assessed by a rapid urease test and histopathological examination of biopsy specimens. Biopsies were also taken for antibiotic susceptibility testing. All enrolled patients were treated with triple therapy consisting of clarithromycin, amoxicillin, and pantoprazole for 14 days. C-13 urea breath test was performed 6 weeks after completing the triple therapy to assess eradication and associated point mutations using real-time polymerase chain reaction (PCR).Results:H pylori was eradicated in 42.9% of diabetic patients and 79.3% of control patients, (P < 0.05). In type 2 diabetes mellitus patients, clarithromycin resistance was 64.3% (36/56), while in the control group, clarithromycin resistance was 35.7% (20/58) (P < 0.05). H pylori was eradicated in 14 (70%) of the 20 clarithromycin-susceptible diabetic patients and in only 10 (27.8%) of the 36 clarithromycin-resistant diabetic patients.Conclusion:The H pylori eradication rate was significantly lower and clarithromycin resistance was significantly higher in type 2 diabetics. Alternative and new treatment protocols and antibiotic susceptibility testing are needed to achieve successful eradication rates.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
References1. Louw JA, Marks IN. Peptic ulcer disease. Curr Opin Gastroenterol 2004;20:533–537.LouwJA]]MarksINPeptic ulcer disease.Curr Opin Gastroenterol200420533-5372. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374–1384.MégraudFH pylori antibiotic resistance: prevalence, importance, and advances in testing.Gut2004531374-13843. Tankovic J, Lamarque D, Lascols C, et al. Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. Aliment Pharmacol Ther 2001;15:707–713.TankovicJ]]LamarqueD]]LascolsC&etal;Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy.Aliment Pharmacol Ther200115707-7134. Dzierzanowska-Fangrat K, Rozynek E, Celińska-Cedro D, et al. Antimicrobial resistance of Helicobacter pylori in Poland: a multicentre study. Int J Antimicrob Agents 2005;26:230–234.Dzierzanowska-FangratK]]RozynekE]]Celińska-CedroD&etal;Antimicrobial resistance of Helicobacter pylori in Poland: a multicentre study.Int J Antimicrob Agents200526230-2345. Gulcelik NE, Kaya E, Demirbas B, et al. Helicobacter pylori prevalence in diabetic patients and its relationship with dyspepsia and autonomic neuropathy. J Endocrinol Invest 2005;28:214–217.GulcelikNE]]KayaE]]DemirbasB&etal;Helicobacter pylori prevalence in diabetic patients and its relationship with dyspepsia and autonomic neuropathy.J Endocrinol Invest200528214-2176. Oldensburg B, Diepersloot RJ, Hoekstra JB. High seroprevalence of Helicobacter pylori in diabetes mellitus patients. Dig Dis Sci 1996;41:458–461.OldensburgB]]DieperslootRJ]]HoekstraJBHigh seroprevalence of Helicobacter pylori in diabetes mellitus patients.Dig Dis Sci199641458-4617. Candelli M, Rigante D, Marietti G, et al. Helicobacter pylori, gastrointestinal symptoms, and metabolic control in young type 1 diabetes mellitus patients. Pediatrics 2003;111:800–803.CandelliM]]RiganteD]]MariettiG&etal;Helicobacter pylori, gastrointestinal symptoms, and metabolic control in young type 1 diabetes mellitus patients.Pediatrics2003111800-8038. Gasbarrini A, Ojetti V, Pitocco D, et al. Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1999;11:713–716.GasbarriniA]]OjettiV]]PitoccoD&etal;Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection.Eur J Gastroenterol Hepatol199911713-7169. Gasbarrini A, Ojetti V, Pitocco D, et al. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Scand J Gastroenterol 2000;35:260–263.GasbarriniA]]OjettiV]]PitoccoD&etal;Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus.Scand J Gastroenterol200035260-26310. Bégué RE, Gómez R, Compton T, et al. Effect of Helicobacter pylori eradication in the glycemia of children with type 1 diabetes: a preliminary study. South Med J 2002;95:842–845.BéguéRE]]GómezR]]ComptonT&etal;Effect of Helicobacter pylori eradication in the glycemia of children with type 1 diabetes: a preliminary study.South Med J200295842-84511. Sargýn M, Uygur-Bayramicli O, Sargýn H, et al. Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori. World J Gastroenterol 2003;9:1126–1128.SargýnM]]Uygur-BayramicliO]]SargýnH&etal;Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori.World J Gastroenterol200391126-112812. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175–1186.SuerbaumS]]MichettiPHelicobacter pylori infection.N Engl J Med20023471175-118613. Malfertheiner P, Mégraud F, O’Morain C, et al. Current concepts in the management of H pylori infection—the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002;16:167–180.MalfertheinerP]]MégraudF]]O’MorainC&etal;Current concepts in the management of H pylori infection—the Maastricht 2-2000 consensus report.Aliment Pharmacol Ther200216167-18014. Tankovic J, Lamarque D, Lascols C, et al. Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. Pathol Biol (Paris) 2001;49:528–533.TankovicJ]]LamarqueD]]LascolsC&etal;Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy.Pathol Biol (Paris)200149528-53315. Calvet X, Garcia N, López T, et al. A metaanalysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:603–609.CalvetX]]GarciaN]]LópezT&etal;A metaanalysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection.Aliment Pharmacol Ther200014603-60916. Kadayıfcı A, Buyukhatipoğlu H, Koruk M, et al. Turkiye’de H pylori eradikasyonunda PPI, amoksisilin ve klaritromisin tedavisinin etkinliği: meta-analiz. Turk J Gastroenterol 2004;15(suppl 1):5.KadayıfcıA]]BuyukhatipoğluH]]KorukM&etal;Turkiye’de H pylori eradikasyonunda PPI, amoksisilin ve klaritromisin tedavisinin etkinliği: meta-analiz.Turk J Gastroenterol200415517. Aydin A, Onder GF, Akarca US, et al. Klaritromisine duyarli ve direncli olgularda bir ve iki haftal⟩k pantoprazolamoksisilin- klaritromisin tedavilerinin Helicobacter pylori eradikasyonundaki etkinliği. Turk J Gastroenterol 2004;15(suppl 1):151.AydinA]]OnderGF]]AkarcaUS&etal;Klaritromisine duyarli ve direncli olgularda bir ve iki haftal⟩k pantoprazolamoksisilin- klaritromisin tedavilerinin Helicobacter pylori eradikasyonundaki etkinliği.Turk J Gastroenterol20041515118. Sezgin O, Aslan G, Altıntaçs E, et al. Detection of point mutations on 23S rRNA of Helicobacter pylori and resistance to clarithromycin with PCR-RFLP in gastric biopsy specimens in Mersin, Turkey Turk J Gastroenterol 2008;19:163–167.SezginO]]AslanG]]AltıntaçsE&etal;Detection of point mutations on 23S rRNA of Helicobacter pylori and resistance to clarithromycin with PCR-RFLP in gastric biopsy specimens in Mersin,Turkey Turk J Gastroenterol200819163-16719. Quatrini M, Boarino V, Ghidoni A, et al. Helicobacter pylori prevalence in patients with diabetes and its relationship to dyspeptic symptoms. J Clin Gastroenterol 2001;32:215–217.QuatriniM]]BoarinoV]]GhidoniA&etal;Helicobacter pylori prevalence in patients with diabetes and its relationship to dyspeptic symptoms.J Clin Gastroenterol200132215-21720. Malecki M, Bień AI, Galicka-Latalla D, et al. The prevalence of Helicobacter pylori infection and types of gastritis in diabetic patients. The Krakow study. Exp Clin Endocrinol Diabetes 1996;104:365–369.MaleckiM]]BieńAI]]Galicka-LatallaD&etal;The prevalence of Helicobacter pylori infection and types of gastritis in diabetic patients. The Krakow study.Exp Clin Endocrinol Diabetes1996104365-36921. Xia HH, Talley NJ, Kam EP, et al. Helicobacter pylori infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitus. Am J Gastroenterol 2001;96:1039–1046.XiaHH]]TalleyNJ]]KamEP&etal;Helicobacter pylori infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitus.Am J Gastroenterol2001961039-104622. Gasbarrini A, Ojetti V, Pitocco D, et al. Helicobacter pylori infection in patients affected by insulin-dependent diabetes mellitus. Eur J Gastroenterol Hepatol 1998;10:469–472.GasbarriniA]]OjettiV]]PitoccoD&etal;Helicobacter pylori infection in patients affected by insulin-dependent diabetes mellitus.Eur J Gastroenterol Hepatol199810469-47223. Woodward M, Morrison C, Mccoll K. An investigation into factors associated with Helicobacter pylori infection. J Clin Epidemiol 2000;53:175–181.WoodwardM]]MorrisonC]]MccollKAn investigation into factors associated with Helicobacter pylori infection.J Clin Epidemiol200053175-18124. Rosenstock SJ, Jørgensen T, Andersen LP, et al. Association of Helicobacter pylori infection with lifestyle, chronic diseases, body-indices and age at menarche in Danish adults. Scand J Public Health 2000;28:32–40.RosenstockSJ]]JørgensenT]]AndersenLP&etal;Association of Helicobacter pylori infection with lifestyle, chronic diseases, body-indices and age at menarche in Danish adults.Scand J Public Health20002832-4025. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 1991;20:477–490.GwiltPR]]NahhasRR]]TracewellWGThe effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans.Clin Pharmacokinet199120477-49026. Keshavarzian A, Iber FL, Vaeth J. Gastric emptying in patients with insulin-requiring diabetes mellitus. Am J Gastroenterol 1987;82:29–35.KeshavarzianA]]IberFL]]VaethJGastric emptying in patients with insulin-requiring diabetes mellitus.Am J Gastroenterol19878229-3527. Groop LC, De Fronzo RA, Luizi L, et al. Hyperglycemia and absorption of sulphanylurea drugs. Lancet 89;2:129–130.28. Tooke JE. Microvascular haemodynamics in diabetes mellitus. Clin Sci (Lond) 1986;70:119–125.TookeJEMicrovascular haemodynamics in diabetes mellitus.Clin Sci (Lond)198670119-12529. Kong MF, Macdonald IA, Tattersall RB. Gastric emptying in diabetes. Diabet Med 1996;13:112–119.KongMF]]MacdonaldIA]]TattersallRBGastric emptying in diabetes.Diabet Med199613112-11930. McMahon BJ, Hennessy TW, Bensler JM, et al. The Relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003;139:463–469.McMahonBJ]]HennessyTW]]BenslerJM&etal;The Relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections.Ann Intern Med2003139463-46931. Lõivukene K, Maaroos HI, Kolk H, et al. Prevalence of antibiotic resistance of H pylori isolates in Estonia during 1995-2000 in comparison to the consumption of antibiotics used in treatment regimen. Clin Microbial Infect 2002;8:598–603.LõivukeneK]]MaaroosHI]]KolkH&etal;Prevalence of antibiotic resistance of H pylori isolates in Estonia during 1995-2000 in comparison to the consumption of antibiotics used in treatment regimen.Clin Microbial Infect20028598-60332. Ling TKW, Leung WK, Lee CC, et al. The antimicrobial susceptibility of H pylori in Hong Kong (1997-2001). Helicobacter 2002;7:327–329.LingTKW]]LeungWK]]LeeCC&etal;The antimicrobial susceptibility of H pylori in Hong Kong (1997-2001).Helicobacter20027327-32933. Candelli M, Rigante D, Marietti G, et al. Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes. J Pediatr Gastroenterol Nutr 2004;38:422–425.CandelliM]]RiganteD]]MariettiG&etal;Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes.J Pediatr Gastroenterol Nutr200438422-42534. Ojetti V, Migneco A, Nista EC, et al. H pylori re-infection in type 1 diabetes: a 5 years follow-up. Dig Liver Dis 2007;39:286–287.OjettiV]]MignecoA]]NistaEC&etal;H pylori re-infection in type 1 diabetes: a 5 years follow-up.Dig Liver Dis200739286-287
